These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18563832)

  • 21. In vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis.
    Mukkavilli R; Pinjari J; Patel B; Sengottuvelan S; Mondal S; Gadekar A; Verma M; Patel J; Pothuri L; Chandrashekar G; Koiram P; Harisudhan T; Moinuddin A; Launay D; Vachharajani N; Ramanathan V; Martin D
    Eur J Pharm Sci; 2014 Dec; 65():147-55. PubMed ID: 25261338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic properties of TDP4815 after single intravenous and oral administrations to rat, rabbit, monkey, dog and in vitro drug metabolism.
    Chen Y; Cheng D; Tio C; Kagan N; Eisennagel S; Dasgupta M; Tomczuk B; Bone R; Huebert N
    Biopharm Drug Dispos; 2008 Apr; 29(3):127-38. PubMed ID: 18186144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Animal pharmacokinetics and metabolism of the new antimalarial Ro 42-1611 (arteflene).
    Girometta MA; Jauch R; Ponelle C; Guenzi A; Wiegand-Chou RC
    Trop Med Parasitol; 1994 Sep; 45(3):272-7. PubMed ID: 7899803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonist.
    Bungay PJ; Tweedy S; Howe DC; Gibson KR; Jones HM; Mount NM
    Drug Metab Dispos; 2011 Aug; 39(8):1396-405. PubMed ID: 21543556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species.
    Choo EF; Driscoll JP; Feng J; Liederer B; Plise E; Randolph N; Shin Y; Wong S; Ran Y
    Xenobiotica; 2009 Sep; 39(9):700-9. PubMed ID: 19552528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
    Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
    Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
    Deguchi T; Watanabe N; Kurihara A; Igeta K; Ikenaga H; Fusegawa K; Suzuki N; Murata S; Hirouchi M; Furuta Y; Iwasaki M; Okazaki O; Izumi T
    Drug Metab Dispos; 2011 May; 39(5):820-9. PubMed ID: 21282406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys.
    Radulovic LL; Türck D; von Hodenberg A; Vollmer KO; McNally WP; DeHart PD; Hanson BJ; Bockbrader HN; Chang T
    Drug Metab Dispos; 1995 Apr; 23(4):441-8. PubMed ID: 7600909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum.
    Daher W; Pelinski L; Klieber S; Sadoun F; Meunier V; Bourrié M; Biot C; Guillou F; Fabre G; Brocard J; Fraisse L; Maffrand JP; Khalife J; Dive D
    Drug Metab Dispos; 2006 Apr; 34(4):667-82. PubMed ID: 16415117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
    Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
    Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials.
    Gemma S; Campiani G; Butini S; Joshi BP; Kukreja G; Coccone SS; Bernetti M; Persico M; Nacci V; Fiorini I; Novellino E; Taramelli D; Basilico N; Parapini S; Yardley V; Croft S; Keller-Maerki S; Rottmann M; Brun R; Coletta M; Marini S; Guiso G; Caccia S; Fattorusso C
    J Med Chem; 2009 Jan; 52(2):502-13. PubMed ID: 19113955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro-in vivo correlation and translation to the clinical outcome for CJ-13,610, a novel inhibitor of 5-lipoxygenase.
    Matthew Hutzler J; Linder CD; Melton RJ; Vincent J; Daniels JS
    Drug Metab Dispos; 2010 Jul; 38(7):1113-21. PubMed ID: 20375180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomes.
    Idowu OR; Peggins JO; Brewer TG; Kelley C
    Drug Metab Dispos; 1995 Jan; 23(1):1-17. PubMed ID: 7720510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.
    Wong H; Gould SE; Budha N; Darbonne WC; Kadel EE; La H; Alicke B; Halladay JS; Erickson R; Portera C; Tolcher AW; Infante JR; Mamounas M; Flygare JA; Hop CE; Fairbrother WJ
    Drug Metab Dispos; 2013 Dec; 41(12):2104-13. PubMed ID: 24041744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
    Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
    J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid and sensitive quantitative analysis of the new antimalarial N4-[2,6-dimethoxy-4-methyl-5-[(3-trifluoromethyl)phenoxy]-8- quinolinyl]-1,4-pentanediamine in plasma by liquid chromatography and electrochemical detection.
    Karle JM; Olmeda R
    J Chromatogr; 1988 Feb; 424(2):347-56. PubMed ID: 3372627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate.
    Giragossian C; Vage C; Li J; Pelletier K; Piché-Nicholas N; Rajadhyaksha M; Liras J; Logan A; Calle RA; Weng Y
    Drug Metab Dispos; 2015 Jun; 43(6):803-11. PubMed ID: 25805881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans.
    Yamazaki S; Toth LN; Black ML; Duncan JN
    Drug Metab Dispos; 2004 Apr; 32(4):398-404. PubMed ID: 15039292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interspecies comparison of the pharmacokinetics and oral bioavailability of 99-357, a potent synthetic trioxane antimalarial compound.
    Singh RP; Gupta RC; Singh SK
    Eur J Pharm Sci; 2010 Oct; 41(2):312-9. PubMed ID: 20599503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.